势抵抗性前列腺癌个体化药物治疗的研究.pdfVIP

Advances in Clinical Medicine 临床医学进展, 2017, 7(2), 123-129 Published Online June 2017 in Hans. /journal/acm /10.12677/acm.2017.72020 Castration Resistant Prostate Cancer Research of Individualized Drug Therapy 1 2* 2 Bin Hao , Zhifang Ma , Dongwen Wang 1 Shanxi Medical University, Taiyuan Shanxi 2 Department of Urology, The First Hospital of Shanxi Medical University, Taiyuan Shanxi nd rd th Received: May 22 , 2017; accepted: Jun. 23 , 2017; published: Jun. 26 , 2017 Abstract Objective: To study the individualized chemotherapy drug castration resistant prostate cancer (CRPC) clinical effect. Methods: Prospective, randomized, controlled method, will in February 2013 to December 2014, Shanxi medical university first hospital uropoiesis surgical department of 41 patients with CRPC were randomly divided into 2 groups. Treatment group detection TUBB3, ERCC1 gene mRNA and MDR1 gene polymorphism, according to the results of the choice of tar- geted chemotherapy regimens, individualized selection of common three kinds of chemotherapy drugs, including his dorsey, mitoxantrone, cisplatin; More than the control group only with west he match treatment; Change from two groups patients serum TPSA, tumor lesions, bone scan, the patient pain score metrics such as comparison, every three weeks for a cycle, continuous assess- ment after treatment for 6 cycles. Results: 1) after treatment, the treatment group serum TPSA value was 30.9 ± 5.43, the control group, serum TPSA value was 39.1 ± 7.7 curative effect compar- ison between the two groups, the difference was